You just read:

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia

News provided by

Eiger BioPharmaceuticals, Inc.

Mar 26, 2018, 08:00 ET